AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Zacks.com on MSN2h
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin DrugPer the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...
GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...
Central to the lawsuit is the claim that the company's "optimistic forecasts" about CagriSema's effectiveness were unfounded. The suit also contends that the study's "flexible protocol," which ...
Novo Nordisk A/S is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obesity treatment, ...
CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback